A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring

Pitchaya Dilokpattanamongkol 1, Panadda Panusitthikorn 2, Rasda Boonprasert 3, Methee Chayakulkeeree 4 and Porpon Rotjanapan 5*

Abstract

Background: Invasive aspergillosis (IA) is a fatal infectious complication among immunocompromised patients. Aspergillus terreus, the fourth common species can be difficult to treat due to a unique resistance pattern. To date, there has been no report on safety and dose adjustment when intravenous posaconazole is selected in hepatic and renal impairment patient. We present a rare case of intravenous posaconazole use in a hepatic and renal impairment patient with invasive A. terreus pulmonary infection. To our knowledge, this is the first report of intravenous posaconazole use in IA due to A. terreus with hepatic and renal impairment focusing on drug safety and role of therapeutic drug monitoring (TDM).

Case presentation: A 37-year-old previously healthy man with diagnosis of dengue hemorrhagic fever and shock complicated with hepatic and renal impairment proposed to have proven invasive A. terreus pulmonary infection. Due to lack of good clinical response and concern of potential adverse effects whilst on intravenous voriconazole, intravenous posaconazole 300 mg every 48 h was chosen with confirmed therapeutic plasma concentrations. Despite the death of the patient and IA deemed uncontrollable, there were no significant side effects attributable to intravenous posaconazole use demonstrated over a period of 34 days.

Conclusions: Intravenous posaconazole use with TDM implementation maybe a safe alternative option to standard therapy. Therapeutic plasma posaconazole level may be reached at lower dosing regimen in renal and hepatic impairment patient. However, explanations of clinical failure on this patient with immunodeficiency state were multifactorial.

Keywords: Case report, Invasive aspergillosis, Posaconazole, Safety, Therapeutic drug monitoring

* Correspondence: porpon.rot@mahidol.ac.th
5Division of Infectious Diseases, Department of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Invasive fungal infections (IFIs) due to *Aspergillus* species have become a major cause of morbidity and mortality, especially in immunocompromised patients [1]. *A. terreus* has been reported to be the fourth common species isolated according to Antifungal Surveillance Program in 2011 preceding by *A. fumigatus*, *A. flavus*, and *A. niger* [2].

IA has been estimated to occur in 5%-40% of hematologic patients, especially in acute myeloid leukemia and allogeneic hematopoietic stem cell transplant with mortality rate attributable to IA at 25%–50% with standard antifungal regimen available [3, 4]. Treatment option for IA secondary to *A. terreus* may be limited mainly to triazole antifungal group given high level of resistance to amphotericin B either from in vivo or in vitro data [5]. Hence, in some instance when hepatic function is impaired, treatment for this particular IA can be more difficult [6].

Current guidelines by the Infectious Diseases Society of America in the year of 2016 recommends voriconazole as first-line therapy [7]. Voriconazole has fungicidal effect to common strains of *Aspergillus* spp. but has been reported to play a fungistatic effect against *A. terreus* particularly with wide range of minimum inhibitory concentrations (MICs) from 0.125 mg/L to 32 mg/L [8]. Key indicator to good treatment outcome is TDM which is true in all triazole drugs [9]. Therefore, in order to obtain adequate level in critically ill patients, parenteral route is preferred so that gastrointestinal absorption issue is out of concern [10]. However, the parenteral formulations of both voriconazole and posaconazole contain sulphobutylether-b-cyclodextrin (SBECD) as excipients for solubilization of drug with greater proportion in voriconazole that have either been reported being associated with hepatotoxicity or nephrotoxicity [11, 12]. And more importantly, both renal and hepatic dysfunctions are not uncommon in critically ill patients at baseline [10] in which intravenous use of voriconazole should be carefully considered. However, intravenous voriconazole use is allowed in real clinical practice to some period of time in renal insufficiency patients without serious adverse side effects [13] but essentially deems insufficient for cure of IA.

Posaconazole is recognized as an effective substitute in case of treatment failure of voriconazole for IA [7]. Hence, intravenous posaconazole may be a good option for IA treatment when MIC is noted to be less than 0.25 mg/L and plasma concentration above 1.0 mg/L in the setting that renal and/or liver impairment would be a limitation to voriconazole use [14, 15]. However, data on drug safety and role of TDM on parenteral posaconazole use is still lacking in patients with renal and hepatic impairment. Here, we present a rare case of intravenous posaconazole use in critically ill patient with invasive *A. terreus* pulmonary infection and renal and hepatic impairment who had been admitted to Ramathibodi Hospital, Mahidol University, Bangkok, Thailand between November, 2015 and January, 2016 for new insight of this antifungal.

Case presentation

**Hospital course, bacterial infections, and treatment complications**

A previously healthy 37-year-old male was referred to our hospital with a diagnosis of dengue hemorrhagic fever with shock. His clinical course began 6 days prior to transfer when he presented to an outside hospital with fever. He was found to have left sided hemothorax on arrival causing respiratory distress in which intercostal drainage was promptly placed. However, his condition remained unstable following the procedure requiring intravenous norepinephrine for hypotension. His clinical course was shortly complicated by acute renal failure necessitating renal replacement therapy via right internal jugular catheter on hospital day 2. Despite supportive treatment, lactic acidosis was newly demonstrated together with the need for higher dose of vasopressor drug, various antibacterial regimens were prescribed throughout hospitalization and meropenem and vancomycin were selected as initial combination.

On hospital day 3, due to progressive respiratory distress and failure on lung recruitment maneuver, extracorporeal membrane oxygenation (ECMO) was initiated via right femoral catheter. He was also noted to have pancytopenia. Bone marrow study findings were compatible with hemophagocytosis syndrome secondary to dengue infection. Intravenous dexamethasone (10 mg/m²) and intravenous immunoglobulin were started and plasmapheresis replaced immunoglobulin therapy on the following day. Hematologist was able to reverse pancytopenic event 7 days later but profound lymphopenia persisted throughout his hospital course with the highest absolute CD4 count of 90 cells/mm³.

On hospital day 11, ECMO was discontinued and right femoral catheter was removed after stabilization of overall condition. However on hospital day 13, he underwent left below knee amputation for better control of limb ischemia presumably secondary to ECMO complication that had been documented since hospital day 8. His clinical course was also complicated by 1) Cytomegalovirus reactivation during dexamethasone therapy and required brief duration of ganciclovir treatment given no specific organ involvement identified and 2) *Chromobacterium violaceum* pneumonia and secondary bacteremia on hospital day 18. Bacterial pneumonia was very difficult to control that he required a prolonged course of antibiotics consisting of piperacillin/tazobactam and ciprofloxacin to the point that...
left pneumonectomy was indicated on hospital day 46. After the surgery, he was prescribed several short courses of antibiotic treatment mainly in order to prevent gut microbial translocation following numerous events of gastrointestinal bleeding. Hemorrhagic complication was later discovered to be secondary to large stress associated rectal ulcer. He died on hospital day 71 due to massive esophageal bleeding that autopsy findings failed to identify infectious etiology at the bleeding site.

**Proven invasive pulmonary aspergillosis**

Regarding fungal infection risk particularly IA following severe dengue infection, micafungin was begun on hospital day 3 after serum galactomannan (GM) was obtained which later reported to be 2.3 by enzyme-linked immunosorbent assay (ELISA). Liposomal amphotericin B replaced micafungin for new diagnosis of probable IA that chest radiograph now displayed faint opacities in right middle lung field. In addition, anidulafungin was added in response to rapid progression of pulmonary lesions on chest radiograph. After 6 days of combination therapy, serum GM level declined to 0.55 as the lowest value but no change on chest radiograph findings and respiratory status.

On hospital day 18, micafungin replaced anidulafungin in light of possible cardiac toxicity. Bronchoscopy was done to determine the potential pathogenic fungi but biopsy was avoided given very compromised respiratory status. Antifungal regimen had been switched to and fro between liposomal amphotericin B and amphotericin B deoxycholate due to a fear of drug induced cholestatic jaundice from hospital day 21 until day 31 when polyene antifungals were halted completely after a recognition of *A. terreus* growth on every respiratory specimen. Intravenous and nebualized voriconazole and oral fluconosine via nasogastric tube were now chosen. Despite of therapeutic voriconazole levels in the range of 3.29–4.89 mg/L, pulmonary lesions were still growing in size with increment of serum GM to 9.73 and worsening respiratory parameters over a period of 10 days. A decision to switch treatment to intravenous posaconazole was made in view of potential SBECD accumulation. Plasma levels of posaconazole were measured to assure drug exposure adequacy. MICs of current *A. terreus* infection to voriconazole, posaconazole, caspofungin, anidulafungin, micafungin were 0.75, 0.125, 1, 0.004, and 0.064 mg/L, respectively.

Determination of posaconazole concentrations in plasma was performed using validated Ultra Performance Liquid Chromatography-Photo Diode Array (UPLC/PDA), according to the US Food and Drug Administration guidance for bio-analytical method validation [16]. Blood samplings for plasma posaconazole levels were performed dividing into two phases. The first phase took place when posaconazole 300 mg was given every 24 h, spotted plasma levels were obtained to determine the appropriate timing of the following doses in which resulted in a new dosing regimen of every 48-h interval. In the second phase happened when posaconazole 300 mg was given every 48 h, blood samples were collected for pharmacokinetic analysis at 0 h (predose), immediately at the end of infusion, approximately 15 min after the end of infusion, and approximately 4, 8, 12, 24 and 48 h after the start of infusion. After 34-day course of posaconazole with confirmation of therapeutic plasma posaconazole levels almost the entire period of time during posaconazole treatment (0.956–7.099 mg/L), his infection still did not subside. Serum GM prior to his death was 8.97. Autopsy result confirmed diffuse IA in his right lung without evidence of dissemination to other organs as well as no bacterial pneumonia documented. Additional immunological tests also declared impairment of natural killer T-cell function. Plasma posaconazole levels and serum GM are shown in Additional file 1: Figure S1. An additional figure file shows summary of his clinical course [see Additional file 1].

Lever function tests and QTc interval on electrocardiography data prior and during posaconazole treatment are displayed in Table 1. The findings demonstrated a decline in aspartate transaminase (AST) and alanine transferase (ALT) levels significantly after posaconazole use (p =0.005 and 0.028, respectively). On the other hand, there was an increase in alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) levels after posaconazole use with statistical significance (p <0.001 and 0.039, respectively). There were no crucial changes on total bilirubin (TB), direct bilirubin (DB) and

| Table 1 Liver function tests and QTc interval (pre and during posaconazole treatment) |
|--------------------------------------|--------------------------------------|------------------|
|                                      | Pre-posaconazole treatment           | During posaconazole treatment | p-value       |
| Aspartate transaminase (median, range)| 210, 64-982 units/L                  | 109, 48-375 units/L           | 0.005         |
| Alanine transferase (median, range)  | 223, 69-1060 units/L                 | 121, 78-409 units/L           | 0.028         |
| Alkaline phosphatase (median, range) | 143, 60-323 units/L                  | 286, 180-478 units/L          | <0.001        |
| Gamma-glutamyl transpeptidase (median, range) | 104, 33-341 units/L | 146, 84-421 units/L          | 0.039         |
| Total bilirubin (mean+/−SD)          | 22.38+/−10.45 mg/dL                  | 19.57+/−3.42 mg/dL            | 0.124         |
| Direct bilirubin (median, range)     | 16.20, 1.50-26.00 mg/dL              | 13.30, 9.10-16.30 mg/dL       | 0.217         |
| QTc interval(median, range)          | 0.435, 0.350-0.490 s                 | 0.450, 0.400-0.490 s          | 0.060         |
QTc interval. Statistical analyses on relevant parameters to compare the differences prior and during posaconazole therapy were performed using SPSS version 21.0 for Windows (IBM Corp., Armonk, New York). The distribution of continuous variables was determined by Kolmogorov-Smirnov test. All continuous variables were assessed by the Student’s t-test or Wilcoxon Rank Sum test as appropriate. For normally distributed variables, data were described by mean ± standard deviation (SD). For skewed variables were described as median (range). A p value of less than 0.05 was considered significant for all statistic values.

**Discussion**

Invasive *A. terreus* infection is considered a fatal infection given its poor prognosis [17]. One of the explanations to this fact is a unique resistance pattern of the fungus that distinguishes *A. terreus* from other species making polyene antifungal agent not an option [18]. Voriconazole remains the mainstay of treatment of most IA [7] except in a rare instance that precludes individuals from voriconazole use such as pre-existing liver condition or renal impairment that can be a risk of SBECD accumulation particularly intravenous formulation [11].

Posaconazole is conceivably an alternative treatment for IA and also recommended in salvage therapy [7]. Hepatic failure has been rarely reported with posaconazole use [19]. On the other hand, this complication can be found from 2.7% up to 12.4% with voriconazole prescription [20]. SBECD, as a potentially nephrotoxic agent comprising in intravenous triazoles has been revealed recently in numerous clinical studies either in human or animal models not to be a significant threat when recommended dosing is delivered but no data on long-term use thus far [11, 13, 21]. Hence, a concern of antifungal composition causing adverse events may not be a major consequence and posaconazole may be a good option among hepatic and renal impaired individuals given the least SBECD component comparing to other triazoles [12].

Similarly to voriconazole and other agents, TDM is suggested in routine clinical practice [9]. Walsh TJ, et al recommended to maintain plasma posaconazole level above 1 mg/L at all time for treatment success [22] but to date, there have not been any data on plasma posaconazole level in correlation with drug safety. Given an emergence of less common *Aspergillus* spp. including *A. terreus*, specific recommendation to support posaconazole use in order to avoid adverse drug events in hepatic and renal impairment is still lacking.

To our knowledge, this is the first case report that focuses on an association of plasma posaconazole levels and safety in invasive *A. terreus* patient that had both hepatic and renal impairment. We were able to maintain therapeutic plasma posaconazole levels at all time. However, clinical failure was observed in this patient describing as deterioration of respiratory status, worsening of pulmonary radiographs, and persistent isolation of the fungus both pre-and postmortem. The plausible explanations include unrevealing myth about posaconazole in some aspect important to clinical practice especially in similar circumstance and factors unrelated to antifungal therapy. Fundamentally, key indicators to microbiological and clinical success besides optimal supportive measures constitute of at least two elements [23]. Appropriate antimicrobial treatment is the cornerstone. All steps of antimicrobial administration should be taken into account starting from agent selection, appropriate dosing regimen, route of administration, clinical efficacy evaluation, adverse effect awareness, or even therapeutic drug monitoring [24].

The other important component is intact host immune response [25]. Diminished number and/or function of white blood cells including CD4 count has long been realized as a major risk of fungal infection as well as difficult to control of disease [26]. Our patient lost his ability to maintain good immune response both innate and adaptive immune response based on immunological investigations. Therefore, one key component to fungal clearance was missing in which clinical failure can be easily predicted.

We initiated recommended dose of intravenous posaconazole 300 mg daily in the beginning and monitored plasma levels intermittently to assure optimal level. We discovered that at some points, plasma levels rose above 5–7 mg/L persistently which were 5–7 times higher than desired level [9]. Regarding safety concerns, our patient was documented to have liver impairment prior to posaconazole initiation but no significant further deterioration of hepatic parameters but in fact a decline in AST and ALT levels although ALP and GGT were trending up prior to his death. On electrocardiography monitoring throughout hospitalization, QTc prolongation was not an issue as well (0.400–0.490 s) indicating intravenous posaconazole was safe in this aspect to some extent. Nevertheless, the dose of posaconazole was adjusted on several occasions from every 24–120 h. The final dosing regimen was 300 mg every 48 h that we were able to maintain plasma trough levels in the range of 0.946–2.838 mg/L at all time. This might be a hint to future practice that hepatic impaired patient may not require standard once daily dosing but rather less frequent administration given plasma levels were elevated higher than expected and without other logical explanation. Slower hepatic metabolism, especially in critically ill patients, than in normal hepatic function is a possibility [27].

Based on these findings, we may conclude that intravenous posaconazole use may be safe in pre-existing hepatic and renal impairment individuals undergoing renal replacement therapy. The manufacturer’s suggested dosing regimen of posaconazole in renal and liver impairment patients is presented in Table 2.

However, these are based on a single case observation on hepatic and renal impairment taking intravenous posaconazole treatment. This maybe too premature to conclude that posaconazole is safe in every hepatic and renal impaired patients with/without dose adjustment
Table 2  Recommended dose for posaconazole in renal and liver impairment patients [12]

| Population                      | Posaconazole dose adjustment                  |
|---------------------------------|-----------------------------------------------|
| Renal impairment                |                                               |
| Creatinine clearance 20-80 ml/min | No adjustment necessary                       |
| Creatinine clearance < 20 ml/min | No adjustment necessary, monitor for           |
|                                 | breakthrough fungal infections due to         |
|                                 | variability in exposure                       |
| Hepatic impairment              |                                               |
| Child-Pugh A, B, C              | No adjustment necessary                       |

but potentially such patients can reach therapeutic level with lower dosing regimen. Hence, a study at a larger scale is encouraged to verify these observations.

Conclusions

Intravenous posaconazole use at conventional dose in critically ill patients with reduced liver and renal functions may cause unexpectedly elevated posaconazole plasma level but potential adverse events were not observed in correlation with presumptive “supra-and therapeutic values” in this case report. Reduction of maintenance dosage with guidance of TDM may be necessary in order to avoid unaware adverse effects. However, posaconazole therapy was not a success in this case study and the explanation is likely multifactorial.

Additional file

Additional file 1: Figure S1. Course of antifungal therapy, interventions, serum GM and plasma posaconazole levels. (XLSX 369 kb)

Abbreviations

ALP: Alkaline phosphatase; ALT: Alanine transferase; AST: Aspartate transaminase; cells/mm³: cells per milliliter; CrCl: Creatinine clearance; DB: Direct bilirubin; ECMO: Extracorporeal membrane oxygenation; g/dL: gram per deciliter; GGT: Gamma-glutamyl transpeptidase; GM: Galactomannan; IA: Invasive aspergillosis; IFI: Invasive fungal infection; mg/dL: milligram per liter; mg/m²: milligram per square meter; NK: Natural killer; MIC: Minimum inhibitory concentration; SBECID: Sulphobutylether-b-cyclodextrin; TB: Total bilirubin; TDM: Therapeutic drug monitoring

Acknowledgements

The authors would like to thank the Faculty of Medicine, Ramathibodi Hospital, Mahidol University for their permission to conduct this study and the patient and family members who accepted to participate.

Funding

There was supported by Faculty of Medicine, Ramathibodi Hospital, Mahidol University for this case report.

Availability of data and materials

All data supporting the conclusions of this article are included within the article and its additional files.

Author’s contributions

PR, PD, and PP took care of the patient during hospitalization, coordinated the collection of clinical information, and prepared the manuscript. RB and MC participated in the toxicology diagnostic laboratory. All authors read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

The admitting hospital approved the use of patient samples and data and written informed consent was obtained from patient’s spouse for publication of this case report.

Ethics approval and consent to participate

Ethical approval was granted by Research Ethics Committee of the Faculty of Medicine, Ramathibodi Hospital, Mahidol University. Approval no. MURA2015/767.

Author details

1Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayutthaya RoadRatchathewi, Bangkok 10400, Thailand. 2Department of Pharmacy, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road Bangkoknoi, Bangkok 10700, Thailand. 3Clinical Toxicology Laboratory, Siriraj Poison Control Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road Bangkoknoi, Bangkok 10700, Thailand. 4Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road Bangkoknoi, Bangkok 10700, Thailand. 5Division of Infectious Diseases, Department of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.

Received: 5 August 2016 Accepted: 14 January 2017
Published online: 31 January 2017

References

1. Barnes RA. Early diagnosis of fungal infection in immunocompromised patients. J Antimicrob Chemother. 2008;61 Suppl 1:3–6.
2. Pfaffer MA, Messer SA, Woesley LN, Jones RN, Castanheira M. Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance. J Clin Microbiol. 2013;51(8):2571–81.
3. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.
4. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010; 95(4):644–50.
5. Walsh TJ, Petratis V, Petratiene R, Field-Ridley A, Sutton D, Ghanoum M, Sein T, Schaufele R, Peter J, Bacher J, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003; 188(2):305–19.
6. Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol. 2011;49(4):406–13.
7. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):433–42.
8. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaffer MA, Rinaldi MG, Canton E, Turnidge J. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010;48(9):3251–7.
9. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014; 69(5):1162–76.
10. Roberts DJ, Hall R. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol. 2013; 9(1):1067–84.
11. US Food and Drug Administration Antiviral Drugs Advisory Committee. Briefing document for voriconazole (oral and intravenous formulations). 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf.

12. Noxafil® (posaconazole) injection, delayed-release tablets, oral suspension [prescribing information]. Merck & Co., Inc., Whitehouse Station, NJ; 2014. http://www.merck.com/product/usa/pi_circulars/n/noxafil/noxafil_pi.pdf.

13. Alvarez-Lerma F, Allepuz-Palau A, Garcia MP, Angeles Leon M, Navarro A, Sanchez-Ruiz H, Iriatagoyena JR, Luque-Gomez P. Voriconazole Study Group in Critically II P: Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother. 2008;20(1):93–100.

14. Lavenderde M, Bow EJ, Rotstein C, Auttmizguine J, Broady R, Garber G, Haider S, Hussaini T, Husain S, Ovetchkine P, et al. Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol. 2014;25(6):327–43.

15. Meletiadis J, Mavridou E, Melchers WJ, Mouton JW, Verweij PE. Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis. Antimicrob Agents Chemother. 2012;56(3):2524–9.

16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bio-analytical Method Validation. Rockville, MD; 2001. http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf.

17. Hachem R, Gomes IW, El Heloua G, El Zakhme A, Kassis C, Ramos E, Jiang Y, Chaftari AM, Raad II. Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy. J Antimicrob Chemother. 2014;69(11):3148–55.

18. Steinbach WJ, Benjamin Jr DK, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004; 39(2):192–8.

19. Moton A, Krishna G, Ma L, O’Mara E, Prasad P, McLeod J, Preston RA. Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. Curr Med Res Opin. 2010; 26(1):1–7.

20. VFEND® (voriconazole) Product Monograph. Kirkland, QC: Pfizer Canada, Inc.; 2016. https://www.pfizer.ca/sites/g/files/g10028126/f/201605/VFEND_PM_E_187649_26_Jan_2016.pdf.

21. Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291–301.

22. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):12–12.

23. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009; 53(1):24–34.

24. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(6):2896–13.

25. Casadevall A, Profi ski LA. Adjunctive immune therapy for fungal infections. Clin Infect Dis. 2001;33(7):1048–56.

26. Romani L. Immunity to fungal infections. Nat Rev Immunol. 2011;11(4):275–88.

27. Hawker F. Hepatic failure. In: Park G, Shelly M, editors. Pharmacology of the Critically Ill: Fundamentals of Anaesthesia and Acute Medicine. London: BMJ Books; 2001. p. 90–5.